Literature DB >> 7068280

Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.

G Parmiani, M L Sensi, G Carbone, M Colombo, M Pierotti, D Ballinari, J Hilgers, J Hilkens.   

Abstract

To test whether alloimmunization with H-2 or/and non-H-2 different normal tissues may increase the immunity to syngeneic tumors, groups of BALB/c (H-2d) mice were immunized with a series of allogeneic lymphoid cells and then challenged i.p. with syngeneic lymphoma cells. The outgrowth of otherwise lethal doses of the Moloney virus-induced lymphoma YC8 and of its clones was inhibited in BALB/c mice immune to DBA/2 (H-2d), C3Hf (H-2k), C3H.SW (H-2b), C3H.OH (H-2o2) and to B10 background tissues but not in mice immunized to A/He, BALB.K (H-2k) or BALB.B (H-2b) normal tissues. Anti-YC8 effect was also induced by immunizing BALB/c recipients with a pool of five different allogeneic cell lines which included C3Hf, C57BL/6J (H-2b), N:NIH (H-2q), B10.M (H-2f), and DBA/2 lymphoid cells. No growth inhibition of other BALB/c lymphomas induced by Moloney virus (LSTRA), X-rays (RL male I) or urethane (UR-1) was evident in alloimmune mice. In vivo transfer of growth inhibition of YC8 was obtained with BALB/c anti-B10.D2 peritoneal exudate cells in a Winn assay. The ability of these alloimmune lymphoid cells to delay significantly the survival time of BALB/c mice injected with the mixture of immune cell and YC8 cells was abrogated by anti-Thy 1.2 plus C' treatment. In addition, nu/nu BALB/c mice were unable to develop resistance to YC8 outgrowth after alloimmunization. The results of this study show that: (1) syngeneic growth of a lymphoma can be prevented by alloimmunization with normal cells; (2) this cross-reaction involved non-H-2 antigens; (3) the phenomenon appeared to be mediated by T cells.

Entities:  

Mesh:

Year:  1982        PMID: 7068280     DOI: 10.1002/ijc.2910290316

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Immunotherapy of a murine T cell lymphoma localized to the brain.

Authors:  V K Ghant; N S Hiramoto; G Y Gillespie; D K Gauthier; R N Hiramoto
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Authors:  A Eisenthal; Y Skornick; O Merimsky; R Hirsch; V Zakut; I Ron; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

3.  Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.

Authors:  M P Colombo; M Parenza; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Human anti-lymphoma responses generated in vitro and in vivo following sensitization with allogeneic leukocytes.

Authors:  J M Zarling; N E Kay; B Grant; M Yasukawa; F H Bach
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.

Authors:  G Fossati; A Balsari; D Taramelli; M L Sensi; G Pellegris; M Nava; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.

Authors:  M Sensi; L Grazioli; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Recruitment of inflammatory cells to a tumor deposit potentiates the immunotherapeutic effects of interleukin-2.

Authors:  E P Steller; A M Eggermont; W Matthews; P H Sugarbaker
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.

Authors:  B Leshem; E Kedar
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.